Investors Cheer Secondary Offering for Gene-Editing Firm
While most secondary offerings would bring down the price of the stock, this case is different and shareholders are cheering this dilution because it might bring about something greater.
All Work
Chris Lange
2018 Bull/Bear Outlook: Is JPMorgan a Value Trap?
JPMorgan looks cheap compared to the markets in general, but with the run that it saw in 2017 and the outlook for 2018, this could be a steal. Or is it a value trap?
Constellation Brands Sinks Despite Solid Q3 Results
Its shares fell after Constellation Brands reported its fiscal third-quarter financial results before the markets opened on Friday.
Meet Merrill Lynch’s Top Biotech Picks for 2018
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
2018 Bull/Bear Outlook: Can Nike Keep Pace in 2018?
Nike is recognized across the globe as one of the premier names in sports apparel and shoes. While the company merits a premium for its stock, it shouldn’t scare investors away because there is…
Bull/Bear Outlook Disney: Will 2018 Be the Return of the Mouse?
Looking ahead to 2018, Disney may be facing some difficulties, but it stands to disrupt and continue to take market share.
2018 Bull/Bear Outlook for Coca-Cola: A Little Expensive, but Worth It?
Coca-Cola was one of the subpar Dow Jones Industrial Average components in 2017, and this coming year doesn’t look that much better for the stock.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was yet again another positive day for the U.S. broad markets, with all major exchanges hitting a new record high. Although this is only the third trading day of 2018, this raging bull…
How Amazon and Alphabet Are Ganging Up on Apple
Amazon.com, Inc. (NASDAQ: AMZN) and Alphabet Inc. (NASDAQ: GOOG) have each sailed to a new high during this holiday season on the back of strong sales. During this time, these industry giants had one…
Audentes Therapeutics Pulls Off Positive Interim Results
Audentes Therapeutics shares made a handy gain on Thursday after the company announced positive interim data for a midstage trial.
Macy’s Closing More Stores, Updating Holiday Numbers
Macy’s saw its shares take a step back on Thursday after the company reported numbers from its holiday season, as well as updated guidance for the 2017 full year.
Spotify Gears Up for Sneaky IPO
Perhaps one of the biggest initial public offerings for the 2018 year will be Spotify. However, the way that this company has been going about it, most investors might not have even seen this…
Rite Aid Whiffs Big on Q3 Revenues
Shares of Rite Aid stumbled after the specialty retailer released mixed quarterly results late on Wednesday.
Bull/Bear Outlook: Are Investors Still Hungry for McDonald’s in 2018?
While 2017 found McDonald’s near the top of the food chain in terms of its performance within the Dow, up 45%, the restaurant chain will still be hungry in 2018.
2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?
For the Jones Industrial Average to make its 2018 targets, Pfizer and Merck will to have to do their part to help. But they both lagged the markets in 2017.
Wednesday’s Biggest Winners and Losers in the S&P 500
Wednesday was a positive day for the U.S. broad markets, with all major exchanges hitting a new record high. Although this is only the second trading day of 2018, the markets seem to be…
China Blocked for MoneyGram Acquisition
MoneyGram International shares took a big step back on Wednesday after its acquisition was blocked by the U.S. Committee on Foreign Investment in the United States (CFIUS).
Can BlackBerry and Baidu’s Autonomous Vehicles Collaboration Win?
BlackBerry shares made a solid gain to kick off Wednesday after the firm announced that it would be collaborating with Baidu to accelerate the deployment of connected and autonomous vehicle technology.
Sangamo Jumps on Newest Pfizer Collaboration
Sangamo Therapeutics shares made a handy gain on hump day after the firm announced that it would be collaborating with pharma giant Pfizer.
Trevena Surges With FDA Decision
Trevena saw its shares make a handy gain to start out Wednesday after the firm announced that the FDA accepted its most recent NDA for Olinvo.